HAART & the molecular biology of AIDS dementia complex

Indian Journal of Medical Research

Volumn 121, Issue 4, 2005, Pages 256-269

  Saksena, Nitin K ^a,b   Smit, Theresa K ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b Biological Products   (South Africa)

Author keywords

AIDS dementia complex; Antiretroviral therapy; Central nervous system; HIV; HIV dementia

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATEVIRDINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEUROTOXIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; STROMAL CELL DERIVED FACTOR 1; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COST OF ILLNESS; DEVELOPING COUNTRY; DISEASE COURSE; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TISSUE LEVEL; HEART DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INDIA; IRRITABILITY; LIPOATROPHY; LIVER TOXICITY; MACROPHAGE; MITOCHONDRIAL TOXICITY; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NEUROTROPISM; NONHUMAN; OPPORTUNISTIC INFECTION; POPULATION RESEARCH; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV-1; HUMANS;

EID: 18844366641     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43 : 2245-52.
2. Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science 1988; 5 : 586-92.
3. Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, et al. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology 1998; 51 : 221-8.
4. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, et al. Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 2003; 9 : 205-21.
5. Miller EN, Selnes OA, McArthur JC, Satz P, Becker JT, Cohen BA, et al. Neuropsychological performance in HIV-1-infected homosexual men: The Multicenter AIDS Cohort Study (MACS). Neurology 1990; 40 : 197-203.
6. McArthur JC. Neurologic manifestations of AIDS. Medicine (Baltimore) 1987; 66 : 407-37.
7. GlassJD, Wesselingh SL, Selnes OA, McArthur JC. Clinical-neuropathologic correlation in HIV-associated dementia. Neurology 1993; 43 : 2230-7.
8. Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner JP, Tawadros R, et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 1996; 10 : 573-85.
9. Nuovo GJ, Gallery F, MacConnell P, Braun A. In situ detection of polymerase chain reaction-amplified HIV-1 nucleic acids and tumor necrosis factor-alpha RNA in the central nervous system. Am J Pathol 1994; 44 : 659-66.
10. Johnson RT, Glass JD, McArthur JC, Chesebro BW. Quantitation of human immunodeficiency virus in brains of demented and non-demented patients with acquired immunodeficiency syndrome. Ann Neurol 1996; 39 : 392-5.
11. Achim CL, Heyes MP, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest 1993; 91 : 2769-75.
12. Gartner S. HIV infection and dementia. Science 2000; 287 : 602-4.
13. Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. Unique monocyte subset in patients with AIDS dementia. Lancet 1997; 349 : 692-5.
14. Donaldson YK, Bell JE, Ironside JW, Brettle RP, Robertson JR, Busuttil A, et al. Redistribution of HIV outside the lymphoid system with onset of AIDS. Lancet 1994; 343 : 383-5.
15. Kibayashi K, Mastri AR, Hirsch CS. Neuropathology of human immunodeficiency virus infection at different disease stages. Hum Pathol 1996; 27 : 637-42.
16. Keswani SC, Pardo CA, Cherry CL, Hoke A, McArthur JC. HIN-associated sensory neuropathies. AIDS 2002; 16 : 2105-17. Review.
17. Wojna V, Carlson KA, Luo X, Mayo R, Melendez LM, Kraiselburd E, et al. Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: A case study. J Neurovirol 2004; 10 (Suppl 1) : 74-81.
18. Sun B, Rempel HC, Pulliam L. Loss of macrophage-secreted lysozyme in HIV-1-associated dementia detected by SELD1-TOF mass spectrometry 2004; 30 : 1009-12
19. Tornatore C, Chandra R, Berger JR, Major EO. Abstract HIV-1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology 1994; 44 : 481-7.
20. Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, et al. Abundant expression of HIV Nef and Rev proteins in brain astrocytes in vivo is associated with dementia. AIDS 1995; 9 : 1001-8.
21. Kawano H, Rostapshov V, Rosen L, Lai CJ. Genetic determinants of dengue type 4 virus neurovirulence for mice. J Virol 1993; 67 : 6567-75.
22. Watkins BA, Dorn HH, Kelly WB, et al. Specific tropism of HIV-1 for microglial cells in primary human brain cultures. Science 1990; 249 : 549-52.
23. Power C, McArthur JC, Johnson RT, et al. Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol 1994; 68 : 4643-9.
24. Hwang SS, Boyle TJ, Lyerly HK, et al. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991; 253 : 71-4.
25. Chesebro B, Wehrly K, Nishio J, et al. Macrophage tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell tropic isolates: Definition of critical amino acids involved in cell tropism. J Virol 1992; 66 : 6547-54.
26. Korber B T, Kunstman KJ, Patterson BK, et al. Genetic differences between blood and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol 1994, 68 : 7467-81.
27. Di Stefano M, Wilt S, Gray F, et al. HIV type 1 V3 sequences and the development of dementia during AIDS. AIDS Res Hum Retroviruses 1996, 12 : 471-6.
28. Chang J, Jozwiak R, Wang B, et al. Unique HIV type 1 V3 region sequences derived from six different regions of brain: Region-specific evolution within host-determined quasispecies. AIDS Res Hum Retroviruses 1998, 14 : 25-30.
29. Smit TK, Wang B, Ng T, Osborne R, Brew B, Saksena NK. Varied tropism of HIV-1 isolates derived from different regions of adult brain cortex discriminate between patients with and without ADC: Evidence for neurotropic variants. Virology 2001; 279; 509-26.
30. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381 : 667-73.
31. He J, Chen Y, Farza M, et al. CCR3 and CCR5 are co-receptors for HIV-1infection of microglia. Nature 1997; 385 : 645-9.
32. Gendelman HE, Lipton SA, Tardieu M, Bukrinsky MI, Nottet HS. The neuropathogenesis of HIV-1 infection. J Leukoc Biol 1994; 56 : 389-98.
33. Saksena NK, Wang B, Ge YC, Chang J, Dwyer DE, Xiang SH, et al. Region-specific changes, gene duplications, and random deletions in the nef gene from HIV type 1-infected brain tissues and blood of a demented patient. AIDS Res Hum Retroviruses 1997; 13 : 111-6
34. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70 : 8270-6.
35. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 2004; 78 : 10133-48.
36. Lipton SA. Treating AIDS dementia. Science 1997; 13 : 1629-30.
37. Hirsch MS, Conway B, RTD'A quila, et al. Antiretroviral drug resistance testing in adults with HIV infections: implications for clinical management. JAMA 1998; 279 : 1984-91.
38. Hoetelman RM, Profigt M, Mennhorst PL, Mulder JW, Beijen JA. Quantitative determination of 2-2deoxy-3-thiacytidine (lamivudine) in human plasma, saliva and CSF by high performance HPLC with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998; 713 : 387-94.
39. Stellbrink HJ, Eggers C, van Lunzen J, Albrecht H, Greten H. Rapid decay of HIV RNA in the cerebrospinal fluid during antiretroviral combination therapy. AIDS 1997; 11 : 1655-7.
40. Sune C, Brennan L, Stover DR, Klimkait T. Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant variants under drug pressure. Clin Microbiol Infect 2004; 10 : 119-26.
41. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 11 : 4673-80.
42. Venturi G, Catucci M, Romano L, Corsi P, Leoncini F, Valensin PE, et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000; 181 : 740-5.
43. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004; 54 : 6-9.
44. Pratt R, Nichols S, McKinney N, Kwok S, Dankner W, Spector S. Virologic markers of HIV type 1 in cerebrospinal fluid of infected children. J Infect Dis 1996; 174 : 288-93.
45. Ellis R, Seubert P, Motter R, Galasko D, Deutsch R, Heaton RK, et al. Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. Neurosci Lett 1998; 254 : 1-4.
46. Sei S, Stewart S, Farley M, Mueller BU, Lane JR, Robb ML, et al. Evaluation of HIV type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. J Infect Dis 1996; 174 : 1200-6.
47. Kakuda T, Struble K, Piscitelli S. Protease inhibitors for the treatment of HIV infection. Am J Health Syst Pharm 1998; 55 : 233-54.
48. Kim RB, Fromm M, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter Pglycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101 : 289-94.
49. Lin J, Chiba M, Balani S, Chen IW, Kwei GY, Vastag KJ, et al. Species differences in the pharmacokinetics and metabolism of indinavir, a potent HIV protease inhibitor. Drug Metab Dispos 1996; 24 : 1111-20.
50. Sawchuk R, Yang Z. Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. Adv Drug Deliv Rev 1999; 39 : 5-31.
51. Burger D, Kraaijeveld C, Meenhorst P, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993; 7 : 1581-7.
52. Gallo J, Etse J, Doshi K, Boudinot F, Chu C. Hybrid pharmacokinetic models to describe anti-HIV nucleoside brain disposition following parent and prodrug administration in mice. Pharm Res 1991; 8 : 247-53.
53. Brouwers P, Oecarli C, Heyes MP, Moss HA, Wolters PL, Tudor-Williams G, et al. Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens. AIDS 1997; 11 : 59-66.
54. Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect on HIV type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997; 175 : 434-7.
55. Dykstra K, Arya A, Arriola D, Bungay P, Morrison P, Dedrick R. Microdialysis study of zidovudine transport in rat brain. J Pharmacol Exp Ther 1993; 267 : 1227-36.
56. Galinsky R, Hoesterey B, Anderson B. Brain and cerebrospinal fluid uptake of zidovudine in rats after intravenous injection. Life Sci 1990; 47 : 781-8.
57. Hedaya M, Sawchuk R. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J Pharm Sci 1989; 78 : 716-22.
58. Masereeuw R, Jaehde U, Langemeijer M, De Boer A, Breimer D. In vitro and in vivo transport of AZT across the blood-brain barrier and the effect of transport inhibitors. Pharm Res 1994; 11 : 324-30.
59. Sawchuk R, Hedaya M. Modeling the enhanced uptake of zidovudine into cerebrospinal fluid. 1. Effect of probenecid. Pharm Res 1990; 7 : 332-8.
60. Tuntland T, Ravasco R, Al-Habet S, Unadkat J. Efflux of zidovudine and 2′,3′-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. Pharm Res 1994; 11 : 312-7.
61. Wang Y, Sawchuk R. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J Pharm Sci 1995; 84 : 871-6.
62. Wong S, Van Belle K, Sawchuk R. Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. J Pharmacol Exp Ther 1993; 264 : 899-909.
63. Wong S, Wang Y, Sawchuk R. Analysis of zidovudine distribution to specific regions in rabbit brain using microdialysis. Pharm Res 1992; 9 : 332-8.
64. Thomas S, Segal M. The passage of azidodeoxythymidine into and within the central nervous system: does it follow the parent compound, thymidine? J Pharmacol Exp Ther 1997; 281 : 1211-8.
65. Ahluwalia G, Cooney D, Mitsuya H, et al. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol 1987; 36 : 3797-800.
66. Anderson B, Hoesterey B, Baker D, Galinsky R. Uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies. J Pharmacol Exp Ther 1990; 253 : 113-8.
67. Singhal D, Morgan M, Anderson BD. Role of brain tissue localized purine metabolizing enzymes in the central nervous system delivery of anti-HIV agents 2′-beta-fluoro-2′,3′-dideoxyinosine and 2′- beta-fluoro-2′,3′-dideoxyadenosine in rats. Pharm Res 1997; 14 : 786-92.
68. Van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic HIV infection: a phase I/II study. J Infect Dis 1995; 171 : 1166-71.
69. Dudley M, Graham K, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166 : 480-5.
70. Kline M, Dunkle L, Church J, et al. A phase I/II evaluation of stavudine in children with HIV infection. Pediatrics 1999; 96 : 247-52.
71. Rutschmann O, Hirschel B. Antiretroviral therapy: a guide to the most important trials. Schweiz Med Wochenschr 1997; 127 : 436-43.
72. Glynn S, Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci 1998; 87 : 306-10.
73. Brew B, Dunbar N, Druett J, Freund J, Ward P. Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. AIDS 1996; 10 : 1357-60.
74. Filippi C, Sze G, Farber S, Shahmanesh M, Selwyn P. Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology 1998; 206 : 491-8.
75. Ferrando S, Van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J. Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 1998; 12 : 65-70.
76. Eggers C, Van Lunzen J, Buhk T, Stellbrink HJ. HIV infection of the central nervous system is characterized by rapid turnover of viral RNA in cerebrospinal fluid. J Acquir Immune Defic Syndr 1999; 20 : 259-64.
77. Pialoux G, Fournier S, Moulignier A, Poveda J, Clavel F, Dupont B. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. AIDS 1997; 11 : 1302-3.
78. Strain MC, Letendre S, Pillai SK, Russell T, Ignacio CC, Gunthard HF, Good B, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol 2005; 79 : 1772-88.
79. Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS 2001; 15 : 747-51.
80. Wildemann B, Haas J, Ehrhart K, Wagner H, Lynen N, Storch-Hagenlocher B. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients. Neurology 1993; 43 : 2659-63.
81. Schlegel P, Chang S. Physiology of male reproduction: the testes, epididymis, and ductus deferens. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, editors. 7th vol. Campbell's Urology. Philadelphia,Pa: WB Saunders Co.; 1998 p. 1254-86.
82. Lee C, Gottesman M. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest 1998; 101 : 287-8.
83. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5 : 69-81.
84. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999; 13 : 1249-53.
85. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of ADC. AIDS 2004; 18 (Suppl 1): S75-S78.
86. Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslen M. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS 2002 8; 16(16): 2145-9.
87. Brew BJ, Bhalla RB, Paul M, Gallardo H, McArthur JC, Schwartz MK, Price RW. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990; 28 : 556-60.
88. Brew BJ, Perdices M, Darveniza P, Edwards P, Whyte B, Burke WJ, et al. The neurological features of early and 'latent' human immunodeficiency virus infection. Aust N Z J Med 1989; 19 : 700-5.
89. Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 1991; 41 : 69-74.
90. Griffin DE, Wesselingh SL, McArthur JC. Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol 1994; 35 : 592-7.
91. White D, Heaton RK, Monasch AU. Neuropsychological studies of asymptomatic HIV-infected individuals. The HNRC Group. HIV Neurobehavorial Research Center. J Int Neuropsychological Soc 1995; 1 : 304-15.
92. Chang L, Ernst T, Witt MD, Ames N, Walot I, De Silva M, Trivedi N, Speck O, Miller EN. Persistent brain abnoormalities in antiretroviral-naïve HIV patients 3 months after HAART. Antiviral Therapy 2003; 8 : 17-21.
93. Langford TD, Letendre SL, Masliah E. Changing patterns in the neuropathogenesis of HIV during HAART era. Brain Pathology 2003; 13 : 195-210.
94. Hira SK, Dore GJ, Sirisanthana T. Clinical spectrum of HIV/AIDS in Asia Pacific region. AIDS 1998; 12 (Suppl B) : S145-S54.
95. Ranga U, Shankarappa R, Siddappa NB, Ramakrishna L, Nagendran R, Mahalingam M, et al. Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol 2004; 78 : 2586-90.